July 13, 2016 - Expert key opinion leader Dr. Deborah A. Lannigan from Vanderbilt University recently published "that targeting the downstream effectors of MEK1/2, like RSK, are an untapped source of drug targets and that they will generate less side effects than MEK1/2 inhibitors because they regulated fewer effectors". She went on to mention that "based on overwhelming evidence that RSK is involved in a number of diseases that have high moralities it seems surprising that there are no RSK modulators that have pharmacokinetic properties suitable for in vivo use". Read the abstract here

Phoenix Molecular Designs

Our vision is to deliver precision medicine based on the genetic composition of a person’s tumor, creating better solutions for cancer treatments and improving the lives of patients. We focus on patented RSK inhibitors and companion diagnostics for cancers, including those that develop in the brain, breast, colon and prostate.